Developer docs
API playgroundTry for free, no card

Search company profiles

Telcare

Full company profile

uuid00098dq

Namestring
Telcare
Legal namestring
BioTelemetry, Inc.
Websiteurl
gobio.com
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Telcare, founded in 2008 by Joachim Schoss and headquartered in Malvern, Pennsylvania, developed a machine-to-machine (M2M) cellular platform for remote chronic disease management, initially targeting diabetes and later extending to hypertension and chronic heart failure. The company's flagship product, the Telcare Remote Diabetes Management Platform, combined cellular- and web-connected biometric monitoring with proactive and reactive health coaching, population health reporting, and customizable interventions, and notably incorporated an Alexa Skill for voice-based interactions. The technology stack was anchored on proprietary M2M cellular connectivity designed to wirelessly link patients and physicians, reducing friction in chronic care delivery and enabling near real-time data flow outside of clinical settings. Telcare operated with 101-250 employees and raised approximately $63.46 million across four funding rounds between 2010 and 2014, with investors including Sequoia Capital, Norwest, Qualcomm Ventures, and Mosaic Health Solutions.

In July 2016, BioTelemetry, Inc. acquired Telcare's Remote Diabetes Management Platform, absorbing Telcare into its connected health portfolio alongside its core cardiac telemetry business. BioTelemetry was itself acquired by Royal Philips in February 2021 for approximately USD 2.8 billion, at which point Telcare became part of Philips' Connected Care segment under the Philips Ambulatory Monitoring & Diagnostics (AM&D) umbrella. Within AM&D, Telcare's diabetes and chronic care capabilities were complemented and extended by BioTelemetry's later acquisitions, including the July 2020 acquisition of the On.Demand RPM platform from Centene subsidiary Envolve People Care, which made BioTelemetry the exclusive provider of diabetes RPM services to Centene Medicaid members. As an independent operating entity, Telcare has not existed since 2016; its platform and capabilities continue as a product line within Philips AM&D alongside MCOT, ePatch, Remote INR, and EMR integration services across Epic, Cerner, and other major hospital systems.

Short descriptiontext

Telcare developed a cellular M2M remote diabetes management platform with biometric monitoring, health coaching, and population health tools. Founded in 2008, acquired by BioTelemetry in 2016, and now part of Philips Ambulatory Monitoring & Diagnostics.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMalvern, United States
HQ citystring
Malvern
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
remote patient monitoring, diabetes management platform, machine-to-machine healthcare, cellular health technology, chronic disease coaching
Industry3 codes
PRIMARYHLALAGAD
Endocrinology & Diabetes Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLALADAD
Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN)
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code2 codes
  • Services for the Elderly and Persons with Disabilities624120
  • Services for the Elderly and Persons with Disabilities62412
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Remote Patient Monitoring Software
Social media profiles3 records
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1MCOT (Mobile Cardiac Outpatient Telemetry)
Description

Mobile cardiac telemetry monitoring system for arrhythmia detection with FDA clearance and up to 30 days of monitoring capability

gobio.com
+4 more records
Core offering1 text field

Telcare develops a Remote Diabetes Management Platform that combines machine-to-machine (M2M) cellular technology with biometric monitoring devices, web- and mobile-based software, proactive and reactive health coaching, population health reporting, and customizable clinical interventions for diabetes, hypertension, and chronic heart failure. The platform enables real-time data transmission from patient devices to physicians for clinical decision-making and supports voice-based interaction via an Alexa Skill.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Telcare operates as a product line within Philips Ambulatory Monitoring & Diagnostics (formerly BioTelemetry, Inc.), a connected health technology company providing remote cardiac diagnostics, diabetes management, and population health monitoring. The portfolio centers on two flagship cardiac monitoring products: Philips Mobile Cardiac Telemetry (MCOT) offering up to 30 days of continuous 2-channel ECG monitoring with AI-powered SmartDetect arrhythmia detection, and Philips Extended Holter (ePatch) providing 3-14 day continuous Holter recording with Philips medical-grade AI analytics. These are complemented by the Remote INR self-testing platform for warfarin patients, EMR integration services connecting cardiac monitoring data to hospital systems (Epic, Cerner, Allscripts, Philips IntelliSpace ECG, Muse, Geneva Health Solutions, eClinical Works, NextGen, Athena, Epiphany Healthcare, Meditech), the Geneva Healthcare implantable device management platform, and On.Demand RPM coaching for diabetes, hypertension, and heart failure. The Telcare Remote Diabetes Management Platform (acquired 2016) provides mHealth monitoring combining biometric data with coaching interventions. The Boston Scientific LUX-Dx Insertable Cardiac Monitor extends the portfolio to insertable devices. The architecture is a platform-plus-services model where MCOT and ePatch serve as primary monitoring devices, EMR integration provides data delivery infrastructure, and supplementary products address specific care pathways (stroke, post-TAVR, ED discharge, AF ablation, PCP-cardiology collaboration).

Product and service1 record
1Telcare Remote Diabetes Management Platform
CategoryRemote Patient Monitoring
Description

An mHealth platform combining real-time biometric monitoring with cellular- and web-based technology, proactive and reactive health coaching, population health reporting, and customizable interventions for diabetes, hypertension, and chronic heart failure, including an Alexa Skill for voice-based interactions. Acquired by BioTelemetry in July 2016 and operating today as Telcare Medical Supply, LLC within Philips AM&D.

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

In July 2016, BioTelemetry, Inc. announced the acquisition of Telcare's Remote Diabetes Management Platform. This acquisition expanded BioTelemetry's connected health portfolio, adding chronic remote patient monitoring and coaching solutions focused on diabetes, hypertension, and chronic heart failure. Telcare became part of the BioTelemetry family and subsequently Philips following the 2021 acquisition.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration13 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Telcare

Remote Patient Monitoring Softwaregobio.com

Telcare developed a cellular M2M remote diabetes management platform with biometric monitoring, health coaching, and population health tools. Founded in 2008, acquired by BioTelemetry in 2016, and now part of Philips Ambulatory Monitoring & Diagnostics.

What Telcare does

Telcare, founded in 2008 by Joachim Schoss and headquartered in Malvern, Pennsylvania, developed a machine-to-machine (M2M) cellular platform for remote chronic disease management, initially targeting diabetes and later extending to hypertension and chronic heart failure. The company's flagship product, the Telcare Remote Diabetes Management Platform, combined cellular- and web-connected biometric monitoring with proactive and reactive health coaching, population health reporting, and customizable interventions, and notably incorporated an Alexa Skill for voice-based interactions. The technology stack was anchored on proprietary M2M cellular connectivity designed to wirelessly link patients and physicians, reducing friction in chronic care delivery and enabling near real-time data flow outside of clinical settings. Telcare operated with 101-250 employees and raised approximately $63.46 million across four funding rounds between 2010 and 2014, with investors including Sequoia Capital, Norwest, Qualcomm Ventures, and Mosaic Health Solutions.

In July 2016, BioTelemetry, Inc. acquired Telcare's Remote Diabetes Management Platform, absorbing Telcare into its connected health portfolio alongside its core cardiac telemetry business. BioTelemetry was itself acquired by Royal Philips in February 2021 for approximately USD 2.8 billion, at which point Telcare became part of Philips' Connected Care segment under the Philips Ambulatory Monitoring & Diagnostics (AM&D) umbrella. Within AM&D, Telcare's diabetes and chronic care capabilities were complemented and extended by BioTelemetry's later acquisitions, including the July 2020 acquisition of the On.Demand RPM platform from Centene subsidiary Envolve People Care, which made BioTelemetry the exclusive provider of diabetes RPM services to Centene Medicaid members. As an independent operating entity, Telcare has not existed since 2016; its platform and capabilities continue as a product line within Philips AM&D alongside MCOT, ePatch, Remote INR, and EMR integration services across Epic, Cerner, and other major hospital systems.

Telcare firmographics

Firmographics
Name
Telcare
Legal name
BioTelemetry, Inc.
Website
https://gobio.com
Company type
Private
Founded year
1994
Operating status
Acquired
Headcount range
101–250 employees
Short description
Telcare developed a cellular M2M remote diabetes management platform with biometric monitoring, health coaching, and population health tools. Founded in 2008, acquired by BioTelemetry in 2016, and now part of Philips Ambulatory Monitoring & Diagnostics.
Ownership category
akta.pro rank

Telcare industry classification

Industry
Product category
Remote Patient Monitoring Software
NAICS
Services for the Elderly and Persons with Disabilities (624120), Services for the Elderly and Persons with Disabilities (62412)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLALAGAD
Endocrinology & Diabetes Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLALADAD
Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN)
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Remote patient monitoring
  • Diabetes management platform
  • Machine-to-machine healthcare
  • Cellular health technology
  • Chronic disease coaching

Where Telcare is headquartered

Location

Headquarters

HQ city
Malvern
HQ country
United States
HQ region
North America

Markets served

Telcare business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Telcare product offering

Product offering

Core offering

Telcare develops a Remote Diabetes Management Platform that combines machine-to-machine (M2M) cellular technology with biometric monitoring devices, web- and mobile-based software, proactive and reactive health coaching, population health reporting, and customizable clinical interventions for diabetes, hypertension, and chronic heart failure. The platform enables real-time data transmission from patient devices to physicians for clinical decision-making and supports voice-based interaction via an Alexa Skill.

Product overview

Telcare operates as a product line within Philips Ambulatory Monitoring & Diagnostics (formerly BioTelemetry, Inc.), a connected health technology company providing remote cardiac diagnostics, diabetes management, and population health monitoring. The portfolio centers on two flagship cardiac monitoring products: Philips Mobile Cardiac Telemetry (MCOT) offering up to 30 days of continuous 2-channel ECG monitoring with AI-powered SmartDetect arrhythmia detection, and Philips Extended Holter (ePatch) providing 3-14 day continuous Holter recording with Philips medical-grade AI analytics. These are complemented by the Remote INR self-testing platform for warfarin patients, EMR integration services connecting cardiac monitoring data to hospital systems (Epic, Cerner, Allscripts, Philips IntelliSpace ECG, Muse, Geneva Health Solutions, eClinical Works, NextGen, Athena, Epiphany Healthcare, Meditech), the Geneva Healthcare implantable device management platform, and On.Demand RPM coaching for diabetes, hypertension, and heart failure. The Telcare Remote Diabetes Management Platform (acquired 2016) provides mHealth monitoring combining biometric data with coaching interventions. The Boston Scientific LUX-Dx Insertable Cardiac Monitor extends the portfolio to insertable devices. The architecture is a platform-plus-services model where MCOT and ePatch serve as primary monitoring devices, EMR integration provides data delivery infrastructure, and supplementary products address specific care pathways (stroke, post-TAVR, ED discharge, AF ablation, PCP-cardiology collaboration).

Differentiator

Problem solved

Functional benefit

Brands

  • MCOT (Mobile Cardiac Outpatient Telemetry): Mobile cardiac telemetry monitoring system for arrhythmia detection with FDA clearance and up to 30 days of monitoring capability
  • ePatch (Extended Holter)
  • Remote INR
  • BioTel Heart
  • BioTel Heart EMR Integration

Products and services

  • Telcare Remote Diabetes Management Platform An mHealth platform combining real-time biometric monitoring with cellular- and web-based technology, proactive and reactive health coaching, population health reporting, and customizable interventions for diabetes, hypertension, and chronic heart failure, including an Alexa Skill for voice-based interactions. Acquired by BioTelemetry in July 2016 and operating today as Telcare Medical Supply, LLC within Philips AM&D.

Companies that use Telcare

Customer profile

Ideal customer profiles2 records

Telcare technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration13 records

AI capability6 records

Telcare partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BioTelemetry, Inc.coreStrategic or Co-development Partner · 1 January 2016In July 2016, BioTelemetry, Inc. announced the acquisition of Telcare's Remote Diabetes Management Platform. This acquisition expanded BioTelemetry's connected health portfolio, adding chronic remote patient monitoring and coaching solutions focused on diabetes, hypertension, and chronic heart failure. Telcare became part of the BioTelemetry family and subsequently Philips following the 2021 acquisition.

Recent moves5 records

Expansion highlights5 records

Telcare competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Telcare social profiles

Digital presence

Telcare compliance and trust

Trust signal

Compliance1 record

Telcare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Telcare leadership team

Management profile

Number of profiles

Telcare subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Telcare funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Telcare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Telcare

What does Telcare do?

Telcare develops a Remote Diabetes Management Platform that combines machine-to-machine (M2M) cellular technology with biometric monitoring devices, web- and mobile-based software, proactive and reactive health coaching, population health reporting, and customizable clinical interventions for diabetes, hypertension, and chronic heart failure. The platform enables real-time data transmission from patient devices to physicians for clinical decision-making and supports voice-based interaction via an Alexa Skill.

Is Telcare a public or private company?

Telcare is a private company. It is classified as corporate owned and is currently acquired.

When was Telcare founded?

Telcare was founded in 1994. It employs 101 to 250 people.

Where is Telcare based?

Telcare is headquartered in Malvern, United States, in the North America region.

Does Telcare have an API?

No public API is recorded for Telcare.

What industry is Telcare in?

Telcare's product category is Remote Patient Monitoring Software. Its primary akta.pro industry code is HLALAGAD, Endocrinology & Diabetes Telemedicine Platforms, with a secondary code of HLALADAD, Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN). Its NAICS code is 624120 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTelcare, a Division of BioTelemetry, Inc., Announces Collaboration with Onduo in Diabetes Management ProgramTelcare, a BioTelemetry division, entered a strategic collaboration with Onduo, a Verily-Sanofi joint venture, to supply remote blood glucose systems and data for Onduo's diabetes management program. The partnership targets Type 2 diabetes patients, leveraging Telcare's cellular-enabled glucometer and cloud-based analytics.PrwebZiegler Advises Telcare, Inc. in its Recent Acquisition by BioTelemetry, Inc.Ziegler advised Telcare, Inc. in its acquisition by BioTelemetry, Inc., a wireless medical technology company. The deal expands BioTelemetry's presence in digital population health management, with Telcare's blood glucose monitoring system transmitting real-time data to a cloud-based analytics engine. The combination targets the diabetes market, which has estimated U.S. direct annual costs over $245 billion.PR NewswireResearch and Markets - Global Mobile Healthcare Device Market 2016-2022 - Companies Profiled are Qualcommlife, Athenahealth, Apple, Voxiva, Telcare, Motion Computing & AliveCorResearch and Markets announced the release of a market research report covering the global mobile healthcare device market from 2016-2022, highlighting growth drivers including affordable innovative technologies, increasing lifestyle-related diseases, and rising smartphone adoption. The market is led by segments including SMBG, BP monitors, wearable devices, and cardiac monitors, with reliability being the most critical purchasing factor. The report profiles key industry players including athenahealth, Qualcomm Life, Telcare, Alivcore, and Voxiva.GlobeNewswireTelcare Continues Momentum and Shines Spotlight on Diabetes Education and Prevention in Honor of National Diabetes Awareness MonthTelcare highlighted diabetes awareness during National Diabetes Awareness Month, citing a survey that 28% of Americans plan to raise awareness and 45% know someone with diabetes. The company announced a partnership with Validic and a Glytec study showing 90% of participants reached target glucose levels within three weeks.GlobeNewswireTelcare Diabetes Awareness Index Reveals National Knowledge Gap for the Common and Deadly DiseaseTelcare unveiled its first National Diabetes Awareness Index, revealing a knowledge gap among Americans about diabetes causes, costs, and treatment. The index found 57% of the U.S. population unaware that diabetes can cause heart disease, and 63% don't know the difference between Type 1 and Type 2 diabetes. Technology adoption is rising, with 58% of people with diabetes wanting to use apps to track diets.TechCrunchHow Silicon Valley And Washington Can Come TogetherThe author argues that Silicon Valley and Washington must collaborate on cybersecurity and healthcare IT policy, citing tensions over encryption and regulation. He suggests joint ventures, tech meetups, and policy-savvy consultants to bridge the divide. The piece calls for better communication to enable innovation without hindrance.GlobeNewswireTelcare Names Rick O'Connor as Senior Vice President of MarketingTelcare appointed Rick O'Connor as senior vice president of marketing, bringing over 25 years of healthcare marketing experience. The appointment follows a $32.5 million funding round and a technology patent allowance. O'Connor will drive marketing initiatives and patient engagement efforts.GlobeNewswireTelcare Pioneers Development of the First Cellular-Enabled Glucometer, Secures Patent Allowance for Critical Technology That Supports Improved Diabetes ManagementTelcare announced that the USPTO allowed multiple claims in its pending patent for a cellular-enabled blood glucometer, covering interference prevention. The technology safeguards glucose reading accuracy and is already available in the company's glucometer. The patent supports Telcare's diabetes monitoring solution and its partnership with providers.FinSMEsTelcare Raises $32.5M in Series C FundingTelcare raised $32.5M in Series C funding led by Norwest Venture Partners, with participation from Mosaic Health Solutions and existing investors Sequoia Capital and Qualcomm. The company will use the funds to expand its diabetes platform to related chronic conditions, and NVP partner Casper de Clerq will join the board.GlobeNewswireNorwest Venture Partners Invests in Digital Health Company TelcareTelcare raised $32.5 million in a Series C round led by Norwest Venture Partners, with participation from Mosaic Health Solutions, Sequoia, and Qualcomm. NVP Partner Casper de Clerq will join the board. The funds will expand the company's platform to related chronic conditions.